{"filings":[{"id":108996,"accession_number":"0001193125-26-127609","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Vor Biopharma raises $75M via private placement with TCGX for telitacicept development","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.","Closing expected March 30, 2026; no placement agent used.","Proceeds to advance Phase 3 trials for myasthenia gravis and primary Sjögren's disease.","TCGX managing partner expresses confidence in telitacicept's differentiated profile.","Registration rights agreement to file resale registration statement within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108995,"accession_number":"0001193125-26-009961","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vor Biopharma reports preliminary cash of ~$450M as of Dec 31, 2025","event_type":"other_material","confidence":"medium","bullets":["Cash, cash equivalents and short-term investments ~$450M as of Dec 31, 2025 (preliminary, unaudited).","Company presenting at 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026.","Financial data is subject to change upon completion of audited FY 2025 statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108994,"accession_number":"0001193125-26-000905","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vor Biopharma Chief Development Officer Qing Zuraw departs Dec 31; gets $565K severance + consulting","event_type":"leadership","confidence":"high","bullets":["Dr. Qing Zuraw, Chief Development Officer, resigned effective Dec 31, 2025 to pursue other opportunities.","Separation pay of $565,000 (12 months) plus $115,724 prorated 2025 target bonus; retains $100K signing bonus.","All unvested stock options and RSUs forfeited (no vesting before one-year anniversary).","Company expects to enter a consulting arrangement with Zuraw for Q1 2026 to assist transition.","Separation includes 12-month non-compete, non-disparagement, and standard confidentiality covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125456,"accession_number":"0001193125-25-324768","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio raises $150M in private placement; appoints two new directors","event_type":"other_material","confidence":"high","bullets":["Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.","New/existing investors include RA Capital, Forbion, Frazier Life Sciences, Caligan, Logos, Venrock.","Proceeds to advance telitacicept Phase 3 trials for myasthenia gravis and Sjögren's disease.","Director Sarah Reed resigned; Andrew Levin (RA Capital) and Wouter Joustra (Forbion) appointed.","Levin and Joustra receive standard director fees and option grants of 3,000 shares each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125455,"accession_number":"0001193125-25-311957","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vor Biopharma reprices employee stock options to $8.18; CEO gets 4.16M options repriced","event_type":"other_material","confidence":"high","bullets":["Board reduced exercise price of ~5.2M underwater options to $8.18, the Dec 5, 2025 closing price.","Repriced options originally ranged from $17.80 to $47.60; CEO Jean-Paul Kress repriced 4,164,831 options.","Retention period ends Dec 5, 2027; options exercised earlier retain original exercise price.","CFO Sandy Mahatme received option for 1,388,274 shares at $17.80, reducing to $8.18 after retention period.","Repricing aims to retain employees and avoid dilution from new equity grants or cash comp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125454,"accession_number":"0001193125-25-275862","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vor Biopharma announces $100M public offering of 10M shares at $10 each to fund telitacicept development","event_type":"other_material","confidence":"high","bullets":["10,000,000 shares at $10.00 each; expected net proceeds ~$93.7M (or $107.8M if underwriters' option fully exercised).","Proceeds to advance telitacicept clinical development including Phase 3 trial for primary Sjögren's Disease, plus manufacturing/pre-commercialization.","Offering expected to close November 12, 2025; underwriters have 30-day option for up to 1,500,000 additional shares.","As of Sept 30, 2025, outstanding shares were 9,026,922; offering represents ~111% dilution if fully exercised.","Company believes current cash plus proceeds will fund operations into Q2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125453,"accession_number":"0001193125-25-261723","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio appoints Jeremy Sokolove CMO; amends CDO severance terms","event_type":"leadership","confidence":"high","bullets":["Dr. Jeremy Sokolove appointed CMO effective Nov 3, 2025; has >20 yrs rheumatology/autoimmune R&D experience.","Sokolove previously CMO-in-Residence at Roivant Sciences, SVP at GSK, Head of Immunology at AbbVie.","Vor Bio emphasizes Telitacicept (dual BAFF/APRIL inhibitor) as near-term opportunity for autoimmune patients.","Amended CDO Dr. Qing Zuraw's severance: pro-rated 2025/2026 target bonus if terminated w/o cause, or if resigns after Dec 31, 2025.","Employment amendment effective for five months from Nov 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125452,"accession_number":"0001193125-25-253636","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vor Biopharma reports 48-week Phase 3 data for telitacicept in Sjögren's disease from China","event_type":"other_material","confidence":"low","bullets":["Webcast held Oct 28, 2025 to discuss late-breaking 48-week Phase 3 results from China.","Trial evaluates telitacicept in primary Sjögren's disease; no specific efficacy/safety numbers provided in the filing text.","Stock may react to implied data direction, but actual results are not disclosed in this 8-K excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142190,"accession_number":"0001193125-25-205553","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["3.03","8.01","9.01"],"status":"ready","headline":"Vor Biopharma announces 1-for-20 reverse stock split effective Sept 18, 2025","event_type":"other","confidence":"high","bullets":["Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on September 18, 2025.","Pre-split shares ~136.8M; post-split ~6.84M (subject to fractional share cash-out).","Split-adjusted trading on Nasdaq begins September 19, 2025; new CUSIP 929033207.","Proportionate adjustments to exercise prices and shares under equity plans and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142189,"accession_number":"0001193125-25-193600","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vor Biopharma files corporate presentation; no material new disclosures","event_type":"other_material","confidence":"low","bullets":["Filing furnishes a September 2025 corporate presentation under Item 7.01.","Presentation available on company website; no specific financial or operational updates provided.","No earnings, guidance, or material events announced in the filing or exhibit.","Presentation title: 'Global Science. One Purpose.' — no quantified data included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142188,"accession_number":"0001193125-25-189435","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vor Biopharma announces three director resignations, appoints Sarah Reed","event_type":"leadership","confidence":"high","bullets":["Joshua Resnick, Matthew Patterson, and David Lubner resigned from the Board effective Aug 25-26, 2025; no disagreement cited.","Sarah Reed, General Counsel of RA Capital Management, appointed as independent Class II director effective Aug 27.","Reed receives standard compensation: $40k cash retainer, option to purchase 60k shares, and annual option grants.","Appointment was per securities purchase agreement with RA Capital, which holds >5% of VOR voting stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142187,"accession_number":"0001193125-25-189169","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Vor Biopharma stockholders approve reverse stock split, equity plan amendment; files $119.7M ATM prospectus","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split in range 1-for-5 to 1-for-30; board to determine ratio.","Approved amendment to 2021 equity plan to add 25M shares and reduce annual evergreen from 5% to 4%.","Approved issuance of common stock underlying outstanding warrants for Nasdaq Listing Rule 5635(d) compliance.","Filed prospectus supplement to register up to $119.7M of common stock for ATM offering through Stifel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142186,"accession_number":"0001193125-25-162644","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio appoints Qing Zuraw as CDO, Michel Detheux and Bo Cumbo as directors","event_type":"leadership","confidence":"high","bullets":["Resignation of director Sven (Bill) Ante Lundberg effective July 17, 2025; no disagreement cited.","Qing Zuraw appointed CDO; over 25 years in autoimmune diseases; previously led telitacicept trials at RemeGen.","Zuraw's compensation: $565k base salary, 40% target bonus, $200k signing bonus, 4.37M options, 937k RSUs.","Board expanded to 10; Michel Detheux (CEO iTeos) and Alexander Cumbo (CEO Solid Biosciences) as independent directors.","New directors receive $40k cash retainer, initial 60k options, annual 30k options per standard policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142185,"accession_number":"0001193125-25-157638","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vor Biopharma appoints Sandesh Mahatme as CFO and Chief Business Officer","event_type":"leadership","confidence":"high","bullets":["Sandesh Mahatme appointed CFO, Principal Financial Officer and Principal Accounting Officer, effective July 9, 2025.","Mahatme previously served as President, COO and CFO of National Resilience Inc., raising over $2.5B in capital.","His initial base salary is $480,000, with a 40% target bonus and a $274,000 signing bonus.","Received a grant of 13,882,750 RSUs under the 2023 Inducement Plan; severance includes 12–18 months base salary.","Mahatme also joins as Chief Business Officer, bringing experience from Sarepta and Celgene."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160188,"accession_number":"0001193125-25-147339","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","1.02","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio licenses telitacicept from RemeGen for $125M upfront, raises $175M PIPE, appoints new CEO","event_type":"other_material","confidence":"high","bullets":["License deal: Vor Bio gets ex-China rights to telitacicept (global Phase 3 for gMG) for $125M upfront ($45M cash + $80M warrants); up to $4B+ milestones plus royalties.","Private Placement: $175M gross from pre-funded warrants to buy 700M shares at $0.25/warrant; closing expected June 27, 2025.","CEO change: Robert Ang resigned; Jean-Paul Kress (ex-MorphoSys CEO) appointed CEO and Chairman. Dr. Ang stays as advisor through October.","Cambridge lease terminated: $8.5M termination fee paid; $2.4M letter of credit to be returned. Lease was set to expire in 2030.","Stockholders representing ~63% voting power signed support agreements to approve share issuance and charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160187,"accession_number":"0001193125-25-125833","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Vor Biopharma shareholders OK share increase to 800M, re-elect directors","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 400M to 800M; approved by 65.5M votes for vs 7.7M against.","Class I directors Matthew Patterson and Daniella Beckman re-elected with ~53.4M and ~52.7M votes for.","Ernst & Young LLP ratified as independent auditor for FY2025 with 73.1M votes for.","Annual meeting had 73.2M shares represented, ~58.7% of outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160186,"accession_number":"0001193125-25-123141","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vor Biopharma CEO Robert Ang designated Principal Financial Officer and Principal Accounting Officer","event_type":"leadership","confidence":"high","bullets":["Board designated CEO Robert Ang as principal financial and accounting officer effective May 19, 2025.","No new compensation arrangements were entered into or amended in connection with the designation.","Dr. Ang continues as President, CEO, and director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}